By valuing and structuring their deals appropriately, biotechnology companies can earn higher returns, maintain greater control of intellectual property, and strengthen their partnerships with pharmaceutical companies.
- Alexander Moscho
- Regina A. Hodits
- Josef M.E. Leiter
